An Open-Label, Parallel-Group Study to Determine the Single and Multiple Dose Pharmacokinetics of Vildagliptin and Its Metabolites in Mild, Moderate and Severe Renal Impaired Patients Compared to Age, Sex and Weight-Matched Healthy Volunteers Following Vildagliptin 25 mg and 50 mg Once Daily for 14 Days.
Phase of Trial: Phase I/II
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 23 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2009 Official Title amended as reported by ClinicalTrials.gov.
- 16 Jan 2009 New trial record.